39143-25-4

Basic information

• Product Name: 4-AMINO-1-BENZYL-PIPERIDINE-4-CARBOXYLIC ACID
• Synonyms: 4-AMINO-1-BENZYL-4-PIPERIDINECARBOXYLIC ACID;4-AMINO-1-BENZYL-PIPERIDINE-4-CARBOXYLIC ACID;4-Piperidinecarboxylic acid, 4-aMino-1-(phenylMethyl)-
• CAS NO: 39143-25-4
• Molecular Formula: C₁₃H₁₈N₂O₂
• Molecular Weight: 234.29
• Product Categories: pharmacetical;Carboxylic Acids;Pyrans, Piperidines &Piperazines;Carboxylic Acids;Pyrans, Piperidines & Piperazines
• Mol File: 39143-25-4.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 385.7 °C at 760 mmHg
• Flash Point: 187 °C
• Appearance: /
• Density: 1.207 g/cm³
• Vapor Pressure: 1.23E-06mmHg at 25°C
• Refractive Index: 1.588
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 1.73±0.20(Predicted)
• CAS DataBase Reference: 4-AMINO-1-BENZYL-PIPERIDINE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-1-BENZYL-PIPERIDINE-4-CARBOXYLIC ACID(39143-25-4)
• EPA Substance Registry System: 4-AMINO-1-BENZYL-PIPERIDINE-4-CARBOXYLIC ACID(39143-25-4)

Safety Data

• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 39143-25-4(Hazardous Substances Data)

Usage

General Description

4-Amino-1-Benzyl-Piperidine-4-Carboxylic Acid is a type of organic compound that belongs to the group of piperidines. Piperidines are compounds containing a piperidine ring, which is a saturated heterocycle made up of five carbon atoms and one nitrogen atom. This particular compound is specific due to its benzyl group (a functional group derived from benzene) and carboxylic acid group (consisting of a carbonyl and hydroxyl group), making it a substance of interest in the field of synthetic chemistry. However, detailed information about its potential applications or health effects largely remains to be explored by scientists.

InChI:InChI=1/C13H18N2O2/c14-13(12(16)17)6-8-15(9-7-13)10-11-4-2-1-3-5-11/h1-5H,6-10,14H2,(H,16,17)

Upstream product

• 28936-94-9 8-benzyl-1,3,8-triaza-spiro[4.5]decane-2,4-dione 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 1026596-92-8 di-tert-butyl 8-benzyl-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-1,3-dicarboxylate 

Downstream Products

• 57611-55-9 4-amino-1-benzyl-4-ethoxycarbonylpiperidine 
• 166180-89-8 1-benzyl-4-ethoxycarbonyl-4-(2-oxopiperidino)piperidine 
• 166180-88-7 1-benzyl-4-(5-chlorovaleramido)-4-ethoxycarbonylpiperidine 
• 166181-27-7 1-benzyloxycarbonyl-4-methylaminocarbonyl-4-(2-oxopiperidino)piperidine 
• 166180-94-5 1-benzyloxycarbonyl-4-carboxy-4-(2-oxopiperidino)piperidine 
• 166180-93-4 1-Benzyloxycarbonyl-4-(ethoxycarbonyl)-4-(2-oxopiperidino)-piperidine 
• 951217-68-8 C₁₃H₁₆N₄O₂ 
• 312928-52-2 (4-amino-1-benzyl-piperidin-4-yl)-methanol 
• 1169699-61-9 9-benzyl-4-oxa-1,9-diaza-spiro[5.5]undecan-2-one 
• 1391602-69-9 N-(1-benzyl-4-hydroxymethyl-piperidin-4-yl)-2-chloro-acetamide 
• 1160247-03-9 2-oxo-4-oxa-1,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester 
• 1391602-71-3 1-methyl-4-oxa-1,9-diaza-spiro[5,5]undecan-2-one hydrochloride 
• 368866-30-2 C₂₈H₂₈N₂O₄ 
• 1453814-68-0 C₂₇H₃₂N₄O₂ 

Relevant articles and documents

PROGRANULIN MODULATORS AND METHODS OF USING THE SAME

Provided herein are compounds of formula (I) that modulate progranulin and methods of using the compounds in progranulin- associated disorders, such as Frontotemperal lobe dementia (FTLD).

Opioid receptor agonists and application thereof

The invention discloses compounds and salts thereof that can be used as opioid receptor ligands, a preparation method of the compounds, compositions containing the compounds, and a use of the compounds as [mu] opioid receptor agonists; the compounds are used for treatment of [mu] opioid receptor-mediated related diseases, such as pains and pain-related disorders.

SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.